Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin

Diagnostic Microbiology and Infectious Disease

Volumn 51, Issue 2, 2005, Pages 119-125

  Rybak, Michael J ^a,b,c   Cha, Raymond ^a,b,c   Cheung, Chrissy M ^a   Meka, Venkata G ^d   Kaatz, Glenn W ^a,b,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Resistance; Staphylococcus aureus; Teicoplanin; Vancomycin

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS;

EID: 13444278704     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.09.005     Document Type: Article

References (32)

1. J.R. Aeschlimann, E. Hershberger, and M.J. Rybak Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus Antimicrob. Agents Chemother. 43 1999 1914 1918
2. F.M. Ausubel R. Brent R.E. Kingston D.D. Moore J.G. Seidman J.A. Smith K. Struhl Current protocols in molecular biology 1998 John Wiley & Sons, Inc. New York (NY)
3. S.M.E. Bobin-Dubreux, C. Reverdy, M. Nervi, A. Rougier, F. Bolmstrom, F. Vandenesch, and J. Etienne Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative Antimicrob. Agents Chemother. 45 2001 349 352
4. Centers for Disease Control and Prevention Staphylococcus aureus with reduced susceptibility to vancomycin-United States MMWR Morb. Mortal. Wkly. Rep. 46 1997 765 766
5. Centers for Disease Control and Prevention Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States MMWR Morb. Mortal. Wkly. Rep. 46 1997 813 815
6. R.S. Daum, S. Gupta, R. Sabbagh, and W.M. Milewski Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin; isolation and purification of a constitutively produced protein associated with decreased susceptibility J. Infect. Dis. 166 1992 1066 1072
7. M.J. dos Santos Soares, M.C. da Silva-Carvalho, and B.T. Ferreira-Carvalho Spread of methicillin-resistant Staphylococcus aureus belonging to the Brazilian epidemic clone in a general hospital and emergence of heterogeneous resistance to glycopeptide antibiotics among these isolates J. Hosp. Infect. 44 2000 301 308
8. R. Geisel, F.J. Schmitz, L. Thomas, G. Berns, O. Zetsche, and B. Ulrich Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area J. Antimicrob. Chemother. 43 1999 846 848
9. R.V. Goering, and M.A. Winters A rapid method for the evaluation of chromosomal DNA from gram-positive cocci by field-inversion gel electrophoresis J. Clin. Microbiol. 30 1992 577 580
10. H. Hanaki, K. Kuwahara-Arai, S. Boyle-Vavra, R.S. Daum, H. Labischinski, and K. Hiramatsu Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 J. Antimicrob. Chemother. 42 1998 199 209
11. 2+ and albumin on these drugs Antimicrob. Agents Chemother. 35 1991 1710 1716
12. E. Hershberger, J.R. Aeschlimann, and T. Moldovan Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods Antimicrob. Agents Chemother. 43 1999 717 721
13. K. Hiramatsu, N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, and S. Hori Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 70 73
14. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Orguri, and F.C. Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J. Antimicrob. Chemother. 40 1997 135 136
15. B.P. Howden, P.B. Ward, P.G.P. Charles, T.M. Korman, A. Fuller, P. du Cros, E.A. Grabsch, S.A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P.D.R. Johnson, A.J. Morris, B.C. Mayall, and M.L. Grayson Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin. Infect. Dis. 38 2004 521 528
16. G.W. Kaatz, S.M. Seo, N.J. Dorman, and S.A. Lerner Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis J. Infect. Dis. 162 1989 103 108
17. F.M. MacKenzie, P. Greig, D. Morrison, G. Edwards, and I.M. Gould Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland J. Antimicrob. Chemother. 50 2002 689 697
18. W.M. Milewski, S. Vavra-Boyle, B. Moreira, C.C. Ebert, and R.S. Daum Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked d-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus Antimicrob. Agents Chemother. 40 1996 166 172
19. P.A. Moise-Broder, G.M. Sakoulas, J.J. Schentag, A. Forrest, and R.C. Moellering Jr. Association of the accessory gene regulator specificity group II and response of methicillin-resistant Staphylococcus aureus infections to vancomycin Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002 2002 American Society for Microbiology Washington (DC) (Abstract C1-1059)
20. M.R. Moore, F. Perdreau-Remington, and H.F. Chambers Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis Antimicrob. Agents Chemother. 47 2003 1262 1266
21. P.J. Peterson, P.A. Bradford, W.J. Weiss, T.M. Murphy, P.E. Sum, and S.J. Projan In vitro activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens Antimicrob. Agents Chemother. 46 2002 2595 2601
22. M.C. Ploy, C. Grelaud, C. Martin, L. de Lumley, and F. Denis First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital Lancet 351 1998 1212
23. S.S. Rotun, V. McMath, D.J. Schoonmaker, P.S. Maupin, F.C. Tenover, and B.C. Hil Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia Emerg. Infect. Dis. 5 1999 147 149
24. G. Sakoulas, G.M. Eliopoulos, R.C. Moellering Jr., C. Wennersten, L. Venkataraman, R.P. Novick, and H.S. Gold Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin Antimicrob. Agents Chemother. 46 2002 492 1502
25. G. Sakoulas, G.M. Eliopoulos, R.C. Moellering Jr., R.P. Novick, L. Venkataraman, C. Wennersten, P.C. DeGirolami, M.J. Schwaber, and H.S. Gold Staphylococcus aureus accessory gene regulator (agr) Group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187 2003 929 938
26. D.M. Shlaes, and J.H. Shlaes Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin Clin. Infect. Dis. 20 1995 1071 1073
27. D.M. Shlaes, J.H. Shlaes, V.L. Eteer, P.D. Fey, and R.V. Goering Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex Antimicrob. Agents Chemother. 37 1993 2432 2437
28. K. Sieradzki, R.B. Roberts, and S.W. Haber The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection N. Engl. J. Med. 340 1999 517 523
29. T.L. Smith, M.L. Pearson, and K.R. Wilcox Emergence of vancomycin resistance in Staphylococcus aureus N. Engl. J. Med. 340 1999 493 501
30. F.C. Tenover, R.D. Arbeit, R.V. Goering, P.A. Mickelsen, B.E. Murry, and D.H. Persing Interpreting chromosomal DNA restriction patterns produced by pulse-field electrophoresis: criteria for bacterial strain typing J. Clin. Microbiol. 33 1995 2233 2239
31. F.C. Tenover, M.V. Lancaster, B.C. Hill, C.D. Steward, S.A. Stocker, G.A. Hancock, C.M. O'Hara, N.C. Clark, and K. Hiramatsu Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J. Clin. Microbiol. 36 1998 1020 1027
32. M. Weinbren, and K. Struthers Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy J. Antimicrob. Chemother. 50 2002 293 307